A&O advising Exponent on the sale of BBI Healthcare
Related people
Headlines in this article
Related news and insights
Publications: 04 April 2024
Publications: 03 April 2024
Chief Information Security Officers and cyber whistleblowing: considerations for PE firms
News: 26 March 2024
A&O advises CVC on the financing of its investment in Monbake
Publications: 26 March 2024
Allen & Overy is advising Exponent Private Equity (Exponent) on its agreement to sell BBI Healthcare (BBIH) to Venture Life Group plc (Venture Life).
BBIH is a division of Exponent portfolio company BBI Group and an international provider of differentiated self-care products serving women’s health, diabetes and energy management markets.
The A&O team advising Exponent is led by private equity partner Gordon Milne with senior associate Jeremy Wilkins, associate Beth Tulley and trainee, Angela Chan. The wider A&O team included banking partners Neil Sinha and Adam Zecharia with senior associate James Green and associate Chris Watkins; TSA and IP partner Jim Ford with senior associate George Luther and associate Megan McMellon; employment: partner Sarah Henchoz with associate Stephen Brown; tax counsel Tim Harrop with associate Patrick Rohan; and antitrust partner Alasdair Balfour with senior associate David Weaver, associate Conor Slowey and trainee Alexander Westin-Hardy.
The deal follows a number of transactions on which A&O has advised Exponent since the beginning of 2021, including the acquisition of Gü, the acquisition of Proper and its merger with Eat Real, the acquisitions of Fudco and Everest Dairies, the demerger of Moonpig from the Photobox Group, and on the subsequent IPO of Moonpig.